Reversible sudden sensorineural hearing loss during chronic hepatitis C treat- ment with pegylated interferon-ribavirin : letter to editor
| Journal | Volume 74 - 2011 |
| Issue | Fasc.4 - Letters |
| Author(s) | V. Papastergiou, L. Skorda, P. Lisgos, S. Karatapanis |
| Full article |
 VIEW FREE PDF |
| Liver Clinic, First Department of Internal Medicine, General Hospital of Rhodes, Greece. |
|
Combination of pegylated interferon alpha (PegIFNa) plus ribavirin is currently the standard therapy for patients with chronic hepatitis C (CHC). Sudden hearing loss (SHL) is a rare complication of CHC treatment that is not well documented. We report a case of a 42-year- old Greek man with CHC (genotype 1b) who developed right-sided hearing loss 46 weeks after the initiation of therapy with PegIFNa-2a subcutaneously, at a dose of 180µg/week, and ribavirin orally, at a dose of 1200 mg/day, for a scheduled period of 48 weeks. |
|
© Acta Gastro-Enterologica Belgica. PMID 22319972 |
